Onconova Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology Annual Meeting
June 05, 2023 08:00 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., June 05, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
Cancer Support Community and Equiva Health partner to create new industry standard for digital cancer support
June 02, 2023 15:01 ET
|
Cancer Support Community
WASHINGTON, June 02, 2023 (GLOBE NEWSWIRE) -- The Cancer Support Community (CSC), a nonprofit dedicated to uplifting and strengthening people impacted by cancer, has partnered with Equiva Health...
BioNTech und OncoC4 präsentieren positive Phase-1/2-Daten für Antikörperkandidaten BNT316/ONC-392 bei schwer behandelbarem nicht-kleinzelligen Lungenkarzinom auf ASCO-Jahrestagung
June 02, 2023 06:45 ET
|
BioNTech SE
BNT316/ONC-392 ist ein innovativer monoklonaler anti-CTLA-4-Antikörperkandidat, der gemeinsam von BioNTech und OncoC4 als Mono- oder Kombinationstherapie zur Behandlung verschiedener solider...
BioNTech and OncoC4 Present Positive Phase 1/2 Data for Antibody Candidate BNT316/ONC-392 in Hard-to-Treat NSCLC at ASCO
June 02, 2023 06:45 ET
|
BioNTech SE
BNT316/ONC-392 is a next-generation anti-CTLA-4 monoclonal antibody candidate jointly developed by BioNTech and OncoC4 as monotherapy or combination therapy in a range of solid tumor indications,...
Zai Lab to Highlight New Data from its Oncology Pipeline at 2023 ASCO Annual Meeting
June 01, 2023 16:03 ET
|
Zai Lab Limited
Three poster presentations to provide updates on Zai Lab’s oncology programs focused on unresectable solid tumors, ovarian cancer and gastrointestinal stromal tumors Early Phase 1/2 study data from...
Myriad Genetics Highlights Latest Oncology Portfolio Advancements and New Data at ASCO 2023
June 01, 2023 08:00 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, June 01, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will be highlighting new studies and the recent expansion...
Hofseth Biocare ASA: ADVANCING THE TREATMENT OF PROSTATE CANCER WITH PUBLICATION OF FTH1 RESEARCH ABSTRACT AHEAD OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) MEETING
May 30, 2023 02:40 ET
|
Hofseth Biocare ASA
HBC is pleased to announce the online publication of its abstract titled “Antiproliferative activity of marine-derived oligopeptides combined with androgen receptor inhibition in preclinical cancer...
Theratechnologies présentera des données préliminaires de l’essai de phase I sur l’innocuité et l’efficacité du sudocétaxel zendusortide chez les patients atteints de cancer et soumis à un traitement préalable intensif à l’ASCO 2023
May 25, 2023 17:31 ET
|
Theratechnologies
Signes préliminaires d’activité antitumorale observés chez 36 % des patients, dont deux réponses partielles (RP) et sept patients ayant obtenu une stabilité de la maladie prolongée Les données sur...
Theratechnologies to Present Preliminary Safety and Efficacy Data from Phase 1 Trial of Sudocetaxel Zendusortide in Heavily Pretreated Cancer Patients at ASCO 2023
May 25, 2023 17:31 ET
|
Theratechnologies
Preliminary signs of antitumor activity noted in 36% of patients, with two partial responses (PR) and seven patients with prolonged stable disease (SD) Efficacy and tolerability data from dose...
Novotech Sponsors Oncology Summit with eChina Health and Expert Panel on Drug Development Acceleration with Endpoints for ASCO 2023
May 25, 2023 17:27 ET
|
Novotech
CHICAGO, May 25, 2023 (GLOBE NEWSWIRE) -- Novotech, the leading Asia Pacific centred biotech CRO is sponsoring key oncology focussed expert events for ASCO: a pre-ASCO Summit with eChina Health, and...